0%
Print report
Variant interpretation report

PIK3CA c.331_345del, p.Lys111_Arg115del

NM_006218.4:c.331_345del NP_006209.2:p.(Lys111_Arg115del) In frame indel unknown · exon 2 View identifiers
Classification
Uncertain significance

Variant description:

The PIK3CA NM_006218.4:c.331_345del (NP_006209.2:p.(Lys111_Arg115del)) in-frame deletion variant has not previously been reported in somatic cancers (COSMIC), and lies in a statistically significant hotspot (cancerhotspots.org). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About PIK3CA

PIK3CA encodes the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K), an enzyme that converts the membrane lipid PIP2 into PIP3, thereby activating signaling cascades such as the AKT-mTOR pathway that promote cell survival, proliferation, growth, and motility. It is among the most commonly mutated genes in cancer, and aberrant activation of PI3K signaling is a driving event in tumor development, with the gene implicated in cancers including cervical cancer. Because this pathway is central to tumor growth, it is a major target of cancer therapies, although drug-induced pathway activation can also contribute to treatment resistance.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen PIK3CA VCEP v1.1. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 0
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: no criteria were applied, so ACMG/AMP 2015 Table 5 thresholds for pathogenic, likely pathogenic, benign, or likely benign were not met.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
Not recorded

gnomAD v4.1 allele counts were not recorded for this variant.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

SpliceAI score
0.159 maximum delta

Recorded SpliceAI maximum delta score: 0.159. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied SpliceAI ↗
No screenshot for this evidence
ClinVar submissions
Not recorded

A ClinVar laboratory submission summary was not recorded.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Gain-of-function; curated oncogenicity label: Likely Oncogenic.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant lies in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen PIK3CA VCEP v1.1, with the data and sources behind each one.

28 criteria with recorded statuses: 0 met · 4 not met · 7 not assessed · 17 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

PS2 is not assessed because the required proband, parental, and tissue-comparison data are unavailable; PM6, PP1, and BS4 are not applicable under the VCEP specification.

Not met · 4 · evaluated, threshold not reached

PM1 VCEPNot met: residues 111-115 fall outside all four approved PIK3CA domains, whose nearest listed interval ends at residue 108. Details ▾Hide ▴
Reasoning

The governing Brain Malformations VCEP limits PM1_Supporting to residues affecting critical functional domains listed in Table 4. The variant is NP_006209.2:p.(Lys111_Arg115del), affecting residues 111-115. The authoritative PIK3CA domain table lists the kinase Ras-binding domain at residues 173-292, kinase domains at 322-483 and 797-1068, and the adaptor binding domain at 31-108. Residues 111-115 fall outside every approved domain. The VCEP full-text file clingen_brainmalform_acmg_specifications_v1_1.pdf was searched for c.331_345del, p.Lys111_Arg115del, and p.K111_R115del; no exact variant entry was found. The collected Cancer Hotspots result does not change the decision because this VCEP rule specifies domain membership and does not name a hotspot route.

VCEP rule
Residues affecting critical functional domains provided in Table 4 for each gene.
Evidence considered
  • vcep_materials.json domain_tables.PIK3CA: Kinase Ras-binding domain 173-292; kinase domains 322-483 and 797-1068; adaptor binding domain (PI3K ABD) 31-108.
  • prefetch.json normalization: NM_006218.4:c.331_345del produces NP_006209.2:p.(Lys111_Arg115del), affecting residues 111-115.
  • clingen_brainmalform_acmg_specifications_v1_1.pdf full-text search for c.331_345del, p.Lys111_Arg115del, and p.K111_R115del returned no exact variant entry.
  • The collected Cancer Hotspots result reports a K111 hotspot, but the governing PM1 rule specifies Table 4 critical-domain residues and does not provide a hotspot route.
Still missing
  • No exact c.331_345del, p.Lys111_Arg115del, or p.K111_R115del entry was found in clingen_brainmalform_acmg_specifications_v1_1.pdf; PM1 was evaluated from its complete Table 4 domain list.
Sources
BA1 VCEPNot met: the variant was absent from gnomAD v2.1, v4.1, and non-cancer subsets, so no allele frequency exceeded the >0.0926% BA1 threshold. Details ▾Hide ▴
Reasoning

BA1 is not met. The governing VCEP threshold is allele frequency >0.0926%. The exact variant NM_006218.4:c.331_345del, also represented as p.Lys111_Arg115del and p.K111_R115del, was absent from gnomAD v2.1, gnomAD v4.1, gnomAD v2.1 non-cancer, and gnomAD v3.1 non-cancer; therefore no observed allele frequency exceeds the BA1 threshold. The VCEP specification file contained no variant-specific entry for the searched notations.

VCEP rule
Allele frequency (>0.0926%). An allele frequency (>0.0926%) was approved. ... Note: this was adjusted from ACMG Guidelines due to maintaining the 5x threshold for benign (consistent with previously established guidelines)
Evidence considered
  • ClinGen Brain Malformations specification, benign-stand-alone BA1 row: Allele frequency (>0.0926%).
  • GNOMAD_V2_1: exact genomic deletion 3-178916942-AAAAGATCCTCAATCG-A was absent.
  • GNOMAD_V4_1: exact genomic deletion 3-179199154-AAAAGATCCTCAATCG-A was absent.
  • GNOMAD_V2_1_NON_CANCER and GNOMAD_V3_1_NON_CANCER: the exact variant was absent in both non-cancer searches.
Still missing
  • No variant-specific entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.
Sources
BS1 VCEPNot met: the variant was absent from gnomAD v2.1, v4.1, and non-cancer subsets, so no allele frequency exceeded the >0.0185% BS1 threshold. Details ▾Hide ▴
Reasoning

BS1 is not met. The governing VCEP threshold is allele frequency >0.0185%. The exact variant NM_006218.4:c.331_345del, also represented as p.Lys111_Arg115del and p.K111_R115del, was absent from gnomAD v2.1, gnomAD v4.1, gnomAD v2.1 non-cancer, and gnomAD v3.1 non-cancer; therefore no observed allele frequency exceeds the BS1 threshold. The VCEP specification file contained no variant-specific entry for the searched notations.

VCEP rule
Allele frequency (>0.0185%). An allele frequency (>0.0185%) was approved. (Supplemental Table 3).
Evidence considered
  • ClinGen Brain Malformations specification, strong BS1 row: Allele frequency (>0.0185%).
  • GNOMAD_V2_1: exact genomic deletion 3-178916942-AAAAGATCCTCAATCG-A was absent.
  • GNOMAD_V4_1: exact genomic deletion 3-179199154-AAAAGATCCTCAATCG-A was absent.
  • GNOMAD_V2_1_NON_CANCER and GNOMAD_V3_1_NON_CANCER: the exact variant was absent in both non-cancer searches.
Still missing
  • No variant-specific entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.
Sources
BS2 VCEPNot met: gnomAD reported no variant occurrences, and no family observations were available to reach the VCEP minimum of 3 homozygotes or heterozygotes. Details ▾Hide ▴
Reasoning

BS2 is not met. The governing VCEP rule requires at least 3 homozygotes in gnomAD or at least 3 heterozygotes in well-phenotyped family members, with homozygous occurrences in gnomAD or ExAC countable. The variant was absent from the available gnomAD v2.1, gnomAD v4.1, and non-cancer searches, and the case evidence contains no well-phenotyped family-member observations; thus the required count of 3 is not present. The VCEP specification file contained no variant-specific entry for the searched notations.

VCEP rule
Award BS2 if ≥3 homozygotes present in gnomAD or ≥3 heterozygous in well phenotyped family members. ... Clinical laboratories are encouraged to accumulate more than 2 (≥3) instances of well phenotyped family members before applying this strong criterion. ... Homozygous occurrences in gnomAD or ExAC can also be counted for this point (≥3).
Evidence considered
  • ClinGen Brain Malformations specification, BS2 row: Award BS2 if ≥3 homozygotes present in gnomAD or ≥3 heterozygous in well phenotyped family members.
  • The same VCEP row states that homozygous occurrences in gnomAD or ExAC can be counted for this point (≥3).
  • GNOMAD_V2_1, GNOMAD_V4_1, GNOMAD_V2_1_NON_CANCER, and GNOMAD_V3_1_NON_CANCER: exact variant absent; no homozygote count was reported.
  • No well-phenotyped family-member observations were present in the case evidence.
Still missing
  • No variant-specific entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.
  • No well-phenotyped family-member genotype observations were available.
Sources

Not assessed · 7 · no assessment recorded

PS2 VCEPNot assessed: no proband allele fraction, confirmed parental testing, or affected-versus-other-tissue allele-fraction comparison is available for the variant. Details ▾Hide ▴
Reasoning

The VCEP requires PS2_Strong only when both Criteria 1 and 2 are fulfilled: the variant is detectable in an affected proband and absent from parental samples with confirmed maternity and paternity, and it is detectable in affected tissue but absent or lower in another tissue. The available case evidence provides no proband-level allele fraction, parental testing, confirmed maternity or paternity, affected-tissue comparison, or family-history data for NM_006218.4:c.331_345del. Therefore PS2 cannot be evaluated.

VCEP rule
Award the PS2_Strong point if Criteria 1 AND Criteria 2 are fulfilled.
Evidence considered
  • The VCEP rule requires both PS2 Criteria 1 and Criteria 2 for PS2_Strong; neither criterion can be established from the available case evidence.
  • The case literature extraction for PMID:29533785 states that the exact five-residue deletion is not mentioned and reports no proband, parental, or segregation observation for it.
Still missing
  • No proband, parental, maternity, paternity, affected-tissue, or comparator-tissue segregation/de novo data are available.
  • No notation of this variant was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt when searched as c.331_345del, p.Lys111_Arg115del, or p.K111_R115del.
Sources
PS3 VCEPNot assessed: no exact-variant functional assay result is available; the only paper reports a different PIK3CA K111delK deletion. Details ▾Hide ▴
Reasoning

The governing VCEP requires functional assay evidence meeting its specified acceptability criteria. The VCEP recognizes phosphorylation, DEPTOR binding, cell survivability, and cell proliferation assays as broadly accepted historically; a publication may support PS3 at the supporting level, while moderate evidence requires 8-34 variants and strong evidence requires 35 or more variants. Evidence above supporting additionally requires independent positive and negative validation controls, with WT and empty vector or blank transfection specified as basic controls and documented technical replicates of at least three for the relevant assay types. The available functional paper (PMID:29533785) does not report NM_006218.4:c.331_345del, p.(Lys111_Arg115del), or p.(K111_R115del); it reports a different single-residue PIK3CA K111delK variant. Therefore, no exact-variant functional result is available to assess PS3 at any strength.

VCEP rule
Brain Malformation Recommendation: Award PS3 if the functional assay meets the acceptability criteria delimited in (PMID: 31892348) with specifications added by the BMVCEP. Quality metrics and minimum validation controls required can be found in Supplementary Document 1.
Evidence considered
  • ClinGen Brain Malformations VCEP specification v1.1, Supplementals, Document 1 (PS3), Functional Assay Validation: the four assay classes are phosphorylation, DEPTOR binding, cell survivability, and cell proliferation; any publication within the spreadsheet can support PS3 at supporting level; evidence above supporting requires positive and negative validation controls; 8-34 variants are required for moderate evidence and 35+ variants for strong evidence.
  • ClinGen Brain Malformations VCEP specification v1.1, Supplemental Table 1: for phosphorylation/DEPTOR binding/cell survivability, WT is the basic positive control, empty vector or blank transfection may be the basic negative control, and technical replicates must be documented in at least triplicate; for cell proliferation, WT and empty vector or blank transfection are required as basic controls and technical replicates are required in triplicate or more.
  • PMID:29533785 paper extraction: functional screening included 29 PIK3CA mutants in Ba/F3 cells, but the exact variant was not mentioned; PIK3CA K111delK, a different single-residue deletion, had the strongest activating mutation score in pooled and individual in-vitro formats.
Still missing
  • The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf contains no entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del.
  • No publication in the available evidence reports a functional assay result for the exact five-residue deletion, so assay controls and variant-specific results cannot be evaluated.
Sources
PS4 VCEPNot assessed: the variant is absent from gnomAD, but no affected-case phenotype counts or qualifying Table 2A case evidence are available to assign PS4 points. Details ▾Hide ▴
Reasoning

The VCEP requires PS4 phenotype points from Table 2A, usable only when the variant meets PM2, with strength determined by Table 2B. The variant is absent from gnomAD v2.1 and v4.1, satisfying the available population prerequisite, but the case materials provide no affected-patient phenotype reports or case-control counts for NM_006218.4:c.331_345del (p.Lys111_Arg115del/p.K111_R115del). No odds ratio or 95% confidence interval can therefore be calculated, and no Table 2A phenotype points can be assigned. The only reviewed paper, PMID:29533785, explicitly does not mention this exact five-residue deletion and reports a different PIK3CA K111delK variant. The governing VCEP file also contains no entry for any of the three searched variant notations.

VCEP rule
Points are assigned for phenotype according to (Table 2A). Phenotype criteria can only be used if the variant is absent from controls (PM2). Strength of evidence is determined by points according to (Table 2B). PS4 = 3.5-15.75 points
Evidence considered
  • ClinGen Brain Malformations VCEP specification: PS4 phenotype evidence is point-based under Table 2A, requires PM2, and is assigned strength by Table 2B; no variant-specific pre-assigned PS4 code is present.
  • gnomAD v2.1 and v4.1 both report the variant absent, supporting the PM2 prerequisite but not supplying affected-case phenotype points.
  • Literature review of PMID:29533785 found no mention of PIK3CA c.331_345del, p.(K111_R115del), or p.(Lys111_Arg115del); the paper instead reports the different single-residue deletion PIK3CA K111delK.
  • No case-control counts were available; therefore no odds ratio or 95% confidence interval was calculated.
Still missing
  • No affected-patient case series, matched controls, or case-control counts were available, so an odds ratio and 95% confidence interval could not be calculated.
  • No entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.
Sources
PM2 VCEPNot assessed: the variant was absent from four gnomAD datasets, but patient ancestry and an ethnically matched cohort were not documented for the VCEP PM2 requirement. Details ▾Hide ▴
Reasoning

PM2 cannot be fully assessed from the available evidence. The governing VCEP rule requires the variant to be absent or rare in an ethnically matched control cohort population sample, with the VCEP specification applying PM2 at Supporting strength for the one-person maximum. The exact variant was absent from gnomAD v2.1, gnomAD v4.1, gnomAD v2.1 non-cancer, and gnomAD v3.1 non-cancer, but the case evidence does not state the patient's ancestry or identify an ethnically matched cohort, so the required matching condition cannot be verified. The VCEP specification file contained no variant-specific entry for the searched notations.

VCEP rule
Absent/rare from controls in an ethnically-matched cohort population sample ( ≥1).
Evidence considered
  • ClinGen Brain Malformations specification, PM2 Supporting row: Absent/rare from controls in an ethnically-matched cohort population sample ( ≥1).
  • GNOMAD_V2_1: exact genomic deletion absent.
  • GNOMAD_V4_1: exact genomic deletion absent.
  • GNOMAD_V2_1_NON_CANCER and GNOMAD_V3_1_NON_CANCER: exact variant absent.
  • The available case evidence does not provide ancestry or establish that any queried gnomAD population is ethnically matched to the patient.
Still missing
  • No variant-specific entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.
  • Patient ancestry and the identity of an ethnically matched control cohort are not available.
Sources
BS3 VCEPNot assessed: no exact-variant benign functional result is available; the reported K111delK assay tested a different PIK3CA deletion. Details ▾Hide ▴
Reasoning

The governing VCEP defines BS3 as well-established in vitro or in vivo functional studies showing no damaging effect and requires the SVI/BMVCEP quality metrics and minimum validation controls. The available paper does not test or report NM_006218.4:c.331_345del, p.(Lys111_Arg115del), or p.(K111_R115del); it reports a different PIK3CA K111delK deletion in activating assays. Consequently, there is no exact-variant benign functional result from which BS3 can be assessed at supporting or strong strength.

VCEP rule
Brain Malformation Recommendation: Follow recommendations set forth by the SVI in conjunction with specifications added by the Brain Malformation Group for quality metrics and minimum validation controls required (PMID: 31892348) (Supplementary Document 1)
Evidence considered
  • ClinGen Brain Malformations VCEP specification v1.1, BS3: well-established in vitro or in vivo functional studies showing no damaging effect must follow SVI recommendations with Brain Malformation Group specifications for quality metrics and minimum validation controls.
  • PMID:29533785 paper extraction: the exact five-residue deletion was not mentioned; the study instead reports PIK3CA K111delK, a different single-residue deletion, as strongly activating in the reported in-vitro assays.
Still missing
  • The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf contains no entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del.
  • No available functional study reports a no-damaging-effect result for the exact five-residue deletion, so BS3 assay quality and validation requirements cannot be evaluated.
Sources
BP2 ACMG_2015Not assessed: no documented cis/trans observation with a pathogenic PIK3CA variant is available to satisfy the applicable BP2 phase rule. Details ▾Hide ▴
Reasoning

The VCEP specifies BP2 as applicable as originally described. The governing ACMG/AMP wording requires observation in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or in cis with a pathogenic variant in any inheritance pattern. The available case evidence contains no affected-proband, family, parental, laboratory, or other phase observation establishing either relationship for NM_006218.4:c.331_345del, so BP2 cannot be assessed.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • The VCEP BP2 entry is marked "Applicable as originally described" and its original ACMG/AMP summary requires observation in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or in cis with a pathogenic variant in any inheritance pattern.
  • The reviewed case materials document variant normalization and other evidence categories but provide no parental, family, affected-proband phase, cis, or trans observation for this variant.
Still missing
  • No phase or allelic-observation evidence linking NM_006218.4:c.331_345del to a pathogenic PIK3CA variant is available in the reviewed case files.
  • No entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt.
Sources
BP5 ACMG_2015Not assessed: no case documents the variant with an alternate molecular basis for disease. Details ▾Hide ▴
Reasoning

The VCEP applies BP5 as originally described: the variant must be found in a case with an alternate molecular basis for disease. The available case and literature materials contain no such case for NM_006218.4:c.331_345del (p.Lys111_Arg115del/p.K111_R115del), so the criterion cannot be evaluated from the available evidence. The governing VCEP file contains no entry for any of the three searched variant notations.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • ClinGen Brain Malformations VCEP BP5 rule: the variant must be observed in a case with an alternate molecular basis for disease in a different gene.
  • The reviewed case materials contain no qualifying alternate-gene molecular diagnosis for this variant.
Still missing
  • No case report or cohort record documenting this variant with an alternate molecular basis in a different gene was available.
  • No entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.
Sources
Not applicable · 17· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 VCEPNot applicable: the VCEP excludes PVS1 for this gene. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1.1 marks PVS1 as not applicable. The VCEP states: "LOF and/or haploinsufficiency have not been clearly identified as disease mechanisms underlying brain malformations related to these genes, so in general this rule is not applicable. The disease mechanism for these genes is gain of function (GOF)." NM_006218.4:c.331_345del in PIK3CA is an in-frame insertion/deletion of undetermined repeat-region status predicted to produce NP_006209.2:p.(Lys111_Arg115del). This determination was made deterministically from the VCEP criteria specification, prior to LLM adjudication.

VCEP rule
deterministic_prefilter: vcep_not_applicable
Evidence considered
  • Deterministic consequence classification: in_frame_indel_unknown (prefetch.json normalized protein consequence)
  • VCEP criterion policy: vcep_not_applicable
Sources
PS1 N/ANot applicable: PS1 requires a missense variant, and this is an in-frame indel. Details ▾Hide ▴
Reasoning

PS1 (Richards et al. 2015, PMID:25741868) requires the same amino acid change as a previously established pathogenic variant, evaluated regardless of the underlying nucleotide change. NM_006218.4:c.331_345del in PIK3CA is an in-frame insertion/deletion of undetermined repeat-region status predicted to produce NP_006209.2:p.(Lys111_Arg115del). As a result, no altered amino acid exists at this position to compare against any previously established pathogenic missense variant, so PS1's structural prerequisite is not met by this variant class. The ClinGen Brain Malformations Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1.1 applies PS1 as originally described in ACMG/AMP 2015, so the original definition governs. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: in_frame_indel_unknown (prefetch.json normalized protein consequence)
  • VCEP criterion policy: vcep_unchanged
Sources
generic_acmg_combination_rulescspec ↗
PM3 VCEPNot applicable: the VCEP states disease-causing variants are heterozygous, so recessive in-trans evidence is outside PM3's use. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations VCEP marks PM3 as not applicable because disease-causing variants are heterozygous; PM3 is therefore not used for this disorder, regardless of whether phase evidence is available for this variant.

VCEP rule
Not applicable since disease-causing variants are heterozygous.
Evidence considered
  • The VCEP criteria entry for PM3 states applicability = Not Applicable and gives the governing instruction: "Not applicable since disease-causing variants are heterozygous."
Still missing
  • No entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt.
Sources
PM4 VCEPNot applicable: the VCEP explicitly excludes PM4 for these genes, including rare in-frame indels that might cause gain of function. Details ▾Hide ▴
Reasoning

PM4 is not applicable under the Brain Malformations VCEP specification. Although this variant is an in-frame deletion, the VCEP states that PM4 will not be used for these genes because most insertion/deletions are associated with a loss-of-function mechanism, despite recognizing that an in-frame indel could result in gain of function.

VCEP rule
Although there have been reported in-frame deletion/insertions in these genes which cause the overgrowth phenotype, they are exceptionally rare. Most insertion/deletions are associated with a LoF disease mechanism and so this point will still not be used even though we recognize that it is possible that a variant is an in-frame indel that results in a GoF mechanism.
Evidence considered
  • Brain Malformations VCEP PM4 criterion entry: PM4 is marked Not Applicable for this VCEP; the variant is NM_006218.4:c.331_345del, an in-frame deletion predicted as p.(Lys111_Arg115del).
Sources
PM5 N/ANot applicable: PM5 requires a missense variant, and this is an in-frame indel. Details ▾Hide ▴
Reasoning

PM5 (Richards et al. 2015, PMID:25741868) requires a novel missense change at an amino acid residue where a different missense change has previously been determined to be pathogenic. NM_006218.4:c.331_345del in PIK3CA is an in-frame insertion/deletion of undetermined repeat-region status predicted to produce NP_006209.2:p.(Lys111_Arg115del). As a result, no missense change exists at this residue to compare against a different pathogenic missense change at the same position, so PM5's structural prerequisite is not met by this variant class. The ClinGen Brain Malformations Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1.1 applies PM5 as originally described in ACMG/AMP 2015, so the original definition governs. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: in_frame_indel_unknown (prefetch.json normalized protein consequence)
  • VCEP criterion policy: vcep_unchanged
Sources
generic_acmg_combination_rulescspec ↗
PM6 VCEPNot applicable: the VCEP directs that assumed de novo evidence without confirmed paternity and maternity is addressed through PS2 and not used as PM6. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks PM6 as not applicable and states that assumed de novo evidence without confirmed paternity and maternity is addressed according to PS2 and will not be used.

VCEP rule
Assumed de novo, but without confirmation of paternity and maternity
Evidence considered
  • The VCEP CSPEC entry marks PM6 not applicable and says this point is addressed according to PS2 and will not be used.
Sources
PP1 VCEPNot applicable: the VCEP excludes PP1 because these disease-causing variants are germline mosaic, de novo, or mosaic. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks PP1 not applicable because disease-causing variants in this framework are germline mosaic, de novo, or mosaic; therefore co-segregation with affected family members is not used.

VCEP rule
Co-segregation with disease in multiple affected family members
Evidence considered
  • The VCEP CSPEC entry marks PP1 not applicable and gives the reason that disease-causing variants are germline mosaic, de novo, or mosaic.
Sources
PP2 N/ANot applicable: PP2 is restricted to missense constraint, whereas c.331_345del is an in-frame deletion rather than a missense variant. Details ▾Hide ▴
Reasoning

The Brain Malformations VCEP PP2 rule evaluates missense constraint and awards PP2 when the ExAC/gnomAD missense-constraint z-score exceeds 3.09; it is applicable to PIK3CA. This variant is an in-frame deletion, NM_006218.4:c.331_345del, p.(Lys111_Arg115del), not a missense variant. Therefore PP2 is outside the variant type named by the governing rule, and no missense-constraint z-score is applicable.

VCEP rule
Missense constraint computed in ExAC/gnomAD was utilized. Award PP2 if the z-score > 3.09. (applicable to MTOR, PIK3CA and AKT3 but not PIK3R2).
Evidence considered
  • vcep_materials.json PP2 rule: missense constraint computed in ExAC/gnomAD, with PP2 awarded when z-score > 3.09 for PIK3CA.
  • prefetch.json normalization: NM_006218.4:c.331_345del produces p.(Lys111_Arg115del); the case consequence is an in-frame deletion, not a missense substitution.
Sources
PP3 VCEPNot applicable: the VCEP excludes PP3 because these PIK3CA variants are gain-of-function and traditional pathogenicity predictors assess loss-of-function mechanisms. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations VCEP explicitly excludes PP3 for these PIK3CA variants because the disease mechanism is gain of function and traditional pathogenicity algorithms focus on loss-of-function mechanisms. NM_006218.4:c.331_345del is an in-frame deletion in exon 2 producing p.(Lys111_Arg115del); therefore no computational predictor result is evaluated for PP3.

VCEP rule
This criterion is not applicable since these variants are GOF, and traditional mutation pathogenicity prediction algorithms focus on LOF mechanisms. Use of this criterion can be revisited if there emerges additional published experience with predictive algorithms specifically designed to detect gain of function mutations.
Evidence considered
  • ClinGen Brain Malformations VCEP PP3 rule: PP3 is not applicable for these gain-of-function variants because traditional mutation pathogenicity prediction algorithms focus on loss-of-function mechanisms.
  • Case normalization identifies NM_006218.4:c.331_345del as an in-frame deletion in exon 2 with predicted protein consequence NP_006209.2:p.(Lys111_Arg115del); no PP3 predictor score was used because the criterion is upstream not applicable.
Still missing
  • The searched VCEP file clingen_brainmalform_acmg_specifications_v1_1.pdf.txt contains no entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del; this does not affect the explicit PP3 exclusion.
Sources
PP4 VCEPNot applicable: the VCEP accounts for phenotype specificity under PS4 rather than PP4. Details ▾Hide ▴
Reasoning

PP4 is not applicable under the ClinGen Brain Malformations VCEP because phenotype specificity is accounted for under PS4.

VCEP rule
Not applicable since this criterion is accounted for under PS4.
Evidence considered
  • ClinGen Brain Malformations VCEP criterion entry for PP4 marks it not applicable because this criterion is accounted for under PS4.
Sources
PP5 VCEPNot applicable: this VCEP states that PP5 is not for use. Details ▾Hide ▴
Reasoning

PP5 is not applicable under this VCEP. The specification states that this criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • ClinGen Brain Malformations VCEP criterion entry for PP5 states that the criterion is not for use.
Sources
BS4 VCEPNot applicable: the VCEP excludes BS4 for de novo, germline mosaic, or post-zygotic mutations. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks BS4 not applicable because these are de novo, germline mosaic, or post-zygotic mutations; lack of segregation in affected family members is therefore not used.

VCEP rule
Lack of segregation in affected members of a family.
Evidence considered
  • The VCEP CSPEC entry marks BS4 not applicable because these are de novo, germline mosaic, or post-zygotic mutations.
Sources
BP1 VCEPNot applicable: the VCEP excludes BP1 for this gene. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1.1 marks BP1 as not applicable. The VCEP states: "Not applicable as LOF is not the disease mechanism." NM_006218.4:c.331_345del in PIK3CA is an in-frame insertion/deletion of undetermined repeat-region status predicted to produce NP_006209.2:p.(Lys111_Arg115del). This determination was made deterministically from the VCEP criteria specification, prior to LLM adjudication.

VCEP rule
deterministic_prefilter: vcep_not_applicable
Evidence considered
  • Deterministic consequence classification: in_frame_indel_unknown (prefetch.json normalized protein consequence)
  • VCEP criterion policy: vcep_not_applicable
Sources
BP3 VCEPNot applicable: the VCEP states that these genes lack exon regions that are repetitive and without a known function. Details ▾Hide ▴
Reasoning

BP3 is not applicable under the Brain Malformations VCEP specification. The VCEP states that the specified genes do not have exon regions consisting of repetitive regions without a known function, so repeat-region context cannot activate BP3 for this gene.

VCEP rule
This is not applicable for the genes specified since the exon regions do not have repetitive regions without a known function.
Evidence considered
  • Brain Malformations VCEP BP3 criterion entry: BP3 is marked Not Applicable for this VCEP because the exon regions do not have repetitive regions without a known function.
Sources
BP4 N/ANot applicable: BP4 covers synonymous, noncanonical intronic, or UTR variants, whereas this is an exon 2 in-frame deletion. Details ▾Hide ▴
Reasoning

The VCEP limits BP4 to synonymous variants, intronic positions outside canonical splice sites, and non-coding UTR variants, requiring two of varSEAK, SpliceAI, and MaxEntScan to predict no splicing change. NM_006218.4:c.331_345del is an exonic in-frame deletion in exon 2, outside that scope, so the available SpliceAI max delta score of 0.159 is not evaluated for BP4.

VCEP rule
Award BP4 for a synonymous, intronic positions (except canonical splice sites) or non-coding variants in the UTRs, if two out of three of the splicing prediction tools predicted no impact on splicing function. Not applicable for any variant type except for synonymous, intronic positions (except canonical splice sites) and non-coding variants in the UTRs,. This criterion can be applied when two of three splicing prediction tools predict no splicing change. The splicing prediction tools used are: varSEAK, spliceAI and MaxEntScan.
Evidence considered
  • VCEP BP4 scope: synonymous variants, intronic positions except canonical splice sites, or non-coding UTR variants; two of three named tools must predict no splicing change, using varSEAK, SpliceAI, and MaxEntScan.
  • The case variant is NM_006218.4:c.331_345del, an in-frame deletion located in exon 2; it is outside the VCEP BP4 scope.
  • SpliceAI reports max delta score 0.159, but this prediction is not used because BP4 is not applicable to this variant type and location.
Still missing
  • The searched VCEP file clingen_brainmalform_acmg_specifications_v1_1.pdf.txt contains no entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del; the VCEP applicability rule is nevertheless explicit.
Sources
BP6 VCEPNot applicable: this VCEP states that BP6 is not for use. Details ▾Hide ▴
Reasoning

BP6 is not applicable under this VCEP. The specification states that this criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • ClinGen Brain Malformations VCEP criterion entry for BP6 states that the criterion is not for use.
Sources
BP7 N/ANot applicable: BP7 covers synonymous, noncanonical intronic, or UTR variants, whereas this is an exon 2 in-frame deletion. Details ▾Hide ▴
Reasoning

The VCEP limits BP7 to synonymous variants, intronic positions outside canonical splice sites, and non-coding UTR variants with a non-conserved nucleotide. NM_006218.4:c.331_345del is an exonic in-frame deletion in exon 2, not a synonymous, intronic, or UTR variant; therefore BP7 is not applicable and no conservation or splice score is considered.

VCEP rule
For synonymous, intronic positions (except canonical splice sites) and non-coding variants in the UTRs, if the nucleotide is non-conserved award this point (PhyloP score <0.1).
Evidence considered
  • VCEP BP7 scope: synonymous variants, intronic positions except canonical splice sites, and non-coding UTR variants; the nucleotide must be non-conserved, defined by the VCEP as not present in all vertebrae or PhyloP <0.1.
  • The case variant is NM_006218.4:c.331_345del, an in-frame deletion located in exon 2, so it is outside the VCEP BP7 scope.
Still missing
  • The searched VCEP file clingen_brainmalform_acmg_specifications_v1_1.pdf.txt contains no entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del; the VCEP applicability rule is nevertheless explicit.
Sources

Identifiers

Gene
PIK3CA
Transcript
NM_006218.4
Coding (HGVS c.)
NM_006218.4:c.331_345del
Protein (HGVS p.)
NP_006209.2:p.(Lys111_Arg115del)
GRCh38
chr3:179199154 AAAAGATCCTCAATCG>A
GRCh37
chr3:178916942 AAAAGATCCTCAATCG>A
Location and type
Exon 2 · in frame indel unknown

Gene diagram

Every interpreted variant in PIK3CA, mapped onto the exon structure of NM_006218.4. Select a row to find it on the plot.

PIK3CANM_006218.4
Fetching transcript structure from UCSC…
gnomAD v4.1 Allele count data not recorded
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

Statements

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -27 bp
0.004
SpliceAI acceptor gainat -113 bp
0.002
SpliceAI donor lossat +23 bp
0.037
SpliceAI donor gainat -119 bp
0.159
Pangolin splice lossmagnitude shown
-0.131
Pangolin splice gain
0.022

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

PP3 VCEPNot applicable: the VCEP excludes PP3 because these PIK3CA variants are gain-of-function and traditional pathogenicity predictors assess loss-of-function mechanisms. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations VCEP explicitly excludes PP3 for these PIK3CA variants because the disease mechanism is gain of function and traditional pathogenicity algorithms focus on loss-of-function mechanisms. NM_006218.4:c.331_345del is an in-frame deletion in exon 2 producing p.(Lys111_Arg115del); therefore no computational predictor result is evaluated for PP3.

VCEP rule
This criterion is not applicable since these variants are GOF, and traditional mutation pathogenicity prediction algorithms focus on LOF mechanisms. Use of this criterion can be revisited if there emerges additional published experience with predictive algorithms specifically designed to detect gain of function mutations.
Evidence considered
  • ClinGen Brain Malformations VCEP PP3 rule: PP3 is not applicable for these gain-of-function variants because traditional mutation pathogenicity prediction algorithms focus on loss-of-function mechanisms.
  • Case normalization identifies NM_006218.4:c.331_345del as an in-frame deletion in exon 2 with predicted protein consequence NP_006209.2:p.(Lys111_Arg115del); no PP3 predictor score was used because the criterion is upstream not applicable.
Still missing
  • The searched VCEP file clingen_brainmalform_acmg_specifications_v1_1.pdf.txt contains no entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del; this does not affect the explicit PP3 exclusion.
Sources
BP4 N/ANot applicable: BP4 covers synonymous, noncanonical intronic, or UTR variants, whereas this is an exon 2 in-frame deletion. Details ▾Hide ▴
Reasoning

The VCEP limits BP4 to synonymous variants, intronic positions outside canonical splice sites, and non-coding UTR variants, requiring two of varSEAK, SpliceAI, and MaxEntScan to predict no splicing change. NM_006218.4:c.331_345del is an exonic in-frame deletion in exon 2, outside that scope, so the available SpliceAI max delta score of 0.159 is not evaluated for BP4.

VCEP rule
Award BP4 for a synonymous, intronic positions (except canonical splice sites) or non-coding variants in the UTRs, if two out of three of the splicing prediction tools predicted no impact on splicing function. Not applicable for any variant type except for synonymous, intronic positions (except canonical splice sites) and non-coding variants in the UTRs,. This criterion can be applied when two of three splicing prediction tools predict no splicing change. The splicing prediction tools used are: varSEAK, spliceAI and MaxEntScan.
Evidence considered
  • VCEP BP4 scope: synonymous variants, intronic positions except canonical splice sites, or non-coding UTR variants; two of three named tools must predict no splicing change, using varSEAK, SpliceAI, and MaxEntScan.
  • The case variant is NM_006218.4:c.331_345del, an in-frame deletion located in exon 2; it is outside the VCEP BP4 scope.
  • SpliceAI reports max delta score 0.159, but this prediction is not used because BP4 is not applicable to this variant type and location.
Still missing
  • The searched VCEP file clingen_brainmalform_acmg_specifications_v1_1.pdf.txt contains no entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del; the VCEP applicability rule is nevertheless explicit.
Sources
BP7 N/ANot applicable: BP7 covers synonymous, noncanonical intronic, or UTR variants, whereas this is an exon 2 in-frame deletion. Details ▾Hide ▴
Reasoning

The VCEP limits BP7 to synonymous variants, intronic positions outside canonical splice sites, and non-coding UTR variants with a non-conserved nucleotide. NM_006218.4:c.331_345del is an exonic in-frame deletion in exon 2, not a synonymous, intronic, or UTR variant; therefore BP7 is not applicable and no conservation or splice score is considered.

VCEP rule
For synonymous, intronic positions (except canonical splice sites) and non-coding variants in the UTRs, if the nucleotide is non-conserved award this point (PhyloP score <0.1).
Evidence considered
  • VCEP BP7 scope: synonymous variants, intronic positions except canonical splice sites, and non-coding UTR variants; the nucleotide must be non-conserved, defined by the VCEP as not present in all vertebrae or PhyloP <0.1.
  • The case variant is NM_006218.4:c.331_345del, an in-frame deletion located in exon 2, so it is outside the VCEP BP7 scope.
Still missing
  • The searched VCEP file clingen_brainmalform_acmg_specifications_v1_1.pdf.txt contains no entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del; the VCEP applicability rule is nevertheless explicit.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.16).

1 paper record listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • Systematic Functional Annotation of Somatic Mutations in Cancer.
    The exact variant PIK3CA c.331_345del, p.(K111_R115del) is not explicitly mentioned. The paper reports functional screening of 29 PIK3CA mutants in Ba/F3 cells and identifies PIK3CA K111delK, a different single-residue deletion, as having the strongest activating mutation score in both pooled and individual in-vitro assays; it provides no proband, parental, de novo, or segregation evidence for the specified variant.
    Does not name this variant
    PMID 29533785 ↗
    Quoted passage
    PIK3CAK111delK had the strongest activating mutation score in both the pooled and individual in vitro formats.

    Results, paragraph beginning ‘To examine whether screening individual mutations can overcome the potential masking effect...’

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

ClinVar

This variant is absent from ClinVar.

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.16).

Functional

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Gain-of-function; curated oncogenicity label: Likely Oncogenic.

Somatic

This variant lies in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant lies in a statistically significant hotspot.